$0.73-5.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
Just reported
From iBio, Inc.'s results release of November 10, 2026; its quarterly report has since been filed.
Actual
$1.1M
Guided
—
No guide given
Actual
-$0.05
Guided
—
No guide given
Actual
-$8.3M
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.1M | $100K | +975.00% |
| Profit | -$7.6M | -$5.7M | -32.01% |
| Profit per share | -$0.05 | -$0.11 | +54.55% |
| Free Cash Flow | -$9.5M | -$5.7M | -66.56% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
iBio, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“This was a quarter of focus and execution as we advanced our portfolio of long-acting antibody therapeutics designed to address important challenges in obesity care,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from iBio, Inc.’s Item 2.02 8-K filed November 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.